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Abstract
Background: The pathophysiology of sepsis is due in part to early systemic inflammation. Here
we describe molecular and cellular responses, as well as survival, in A2A adenosine receptor (AR)
agonist treated and untreated animals during experimental sepsis.
Methods: Sepsis was induced in mice by intraperitoneal inoculation of live bacteria (Escherichia coli
or Staphylococcus aureus) or lipopolysaccharide (LPS). Mice inoculated with live bacteria were
treated with an A2A AR agonist (ATL313) or phosphate buffered saline (PBS), with or without the
addition of a dose of ceftriaxone. LPS inoculated mice were treated with ATL313 or PBS. Serum
cytokines and chemokines were measured sequentially at 1, 2, 4, 8, and 24 hours after LPS was
administered. In survival studies, mice were followed until death or for 7 days.
Results: There was a significant survival benefit in mice infected with live E. coli (100% vs. 20%, p
= 0.013) or S. aureus (60% vs. 20%, p = 0.02) when treated with ATL313 in conjunction with an
antibiotic versus antibiotic alone. ATL313 also improved survival from endotoxic shock when
compared to PBS treatment (90% vs. 40%, p = 0.005). The serum concentrations of TNF-α, MIP-
1α, MCP-1, IFN-γ, and IL-17 were decreased by ATL313 after LPS injection (p < 0.05). Additionally,
ATL313 increased the concentration of IL-10 under the same conditions (p < 0.05). Circulating
white blood cell concentrations were higher in ATL313 treated animals (p < 0.01).
Conclusion: Further studies are warranted to determine the clinical utility of ATL313 as a novel
treatment for sepsis.
Background
Approximately 900,000 cases of sepsis occur annually in
the United States, causing roughly 210,000 deaths and
costing almost 17 billion dollars [1]. The overwhelming
inflammation that occurs along with infection during sep-
sis has been the target of several therapeutic interventions
[2]. Unfortunately, despite successful treatment in animal
models, antibody neutralization of individual compo-
nents of this inflammation has not proved beneficial for
the majority of patients in clinical sepsis trials [3].
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Tissue hypoxia, as occurs in sepsis, enhances breakdown
of adenosine triphosphate (ATP) to adenosine mono-
phosphate (AMP), which is then dephosphorylated by the
cytosolic 5'nucloeotidase to adenosine [4]. Adenosine can
bind to four G protein coupled receptors, A1, A2A, A2B, and
A3. The A2A adenosine receptor (AR) is present on inflam-
matory cells including neutrophils, mast cells, monocytes,
macrophages, eosinophils, platelets, and T-cells, and is
involved in anti-inflammatory activities [5]. Activation of
A2A ARs results in an increase in cyclic AMP concentration
in inflammatory cells which is increased further by con-
current type IV phosphodiesterase inhibitors. A2AAR ago-
nists decrease superoxide production in neutrophils,
degranulation of neutrophils, TNF-α production by
monocytes and macrophages, and neutrophil-endothelial
cell adherence [6]. Death occurs in mice deficient for
Adora2a, the A2A AR gene, after exposure to Concanavalin
A liver injury within 8 hours compared to complete sur-
vival in wild-type mice. Pro-inflammatory cytokines are
present in higher concentrations in Adora2a-/- mice when
compared to wild-type mice. Similar findings are
observed in experimental animals exposed to LPS [7].
To assess the broad applicability of A2A AR agonists, spe-
cifically ATL313, in the treatment of experimental sepsis
due to different infections we contrasted survival results in
mice challenged with a gram-negative (Escherichia coli) vs.
gram-positive (Staphylococcus aureus) pathogen or purified
LPS. T cells are increasingly recognized as important in the
pathogenesis of experimental and clinical sepsis [8].
Cytokine expression, inflammation, and therefore out-
comes may differ during experimental sepsis depending
upon the mouse strain and its T cell repertoire. This may
have implications for sepsis therapy including ATL313.
Therefore, we used a mouse strain, C57BL/6, with a pre-
dominantly Th1 phenotype and a mouse strain, Balb/C,
with a predominantly Th2 phenotype to see if there were
differences in outcomes based on underlying T cell phe-
notypes [9].
Sepsis starts as a process of intravascular inflammation
mediated by pro-inflammatory cytokines/chemokines
including TNF-α, MIP-1α, MCP-1, IFN-γ, and IL-17 as well
as anti-inflammatory cytokines, e.g. IL-10 [10]. Therefore,
to better understand the underlying protective effect of
A2A AR agonists, we evaluated cytokines in animals under-
going experimental sepsis with and without the addition
of ATL313. ATL313 is a hundred fold more selective for
the A2A AR than for the A1 AR and twenty fold more selec-
tive than for the A3 AR. Furthermore, ATL313 is more
selective and has a longer half-life (approximately 30 min-
utes in rodents) than its A2A AR agonist predecessors. The
A2A AR agonists are potentially useful therapeutic agents
because, unlike nonspecific AR agonists, A2A AR agonists
do not induce hypotension [11]. We also studied the
peripheral blood of the animals to assess the impact of an
A2A AR agonist on circulating white blood cell concentra-
tions.
Methods
Mice
Female C57BL/6 and BALB/c mice (≅20 g; Jackson Labo-
ratories, Bar Harbor, ME) were housed at 68–72°F with a
12 h light/dark cycle, fed standard laboratory food and
water ad libitum, and were kept under specific pathogen-
free conditions. The protocol used in this study was
approved by the Animal Care and Use Committee of the
University of Virginia.
Reagents and drugs
LPS (E. coli O111:B4) was purchased from Sigma (St.
Louis, MO). The A2A AR agonist, ATL313, (4-{3-(6-amino-
9-(5-cyclopropylcarbamoyl-3,4-dihydroxytetrahydro-
furan-2-yl)-9H-purin-2-yl)prop-2-ynyl}piperidine-1-car-
boxylic acid methyl ester) was supplied by Adenosine
Therapeutics, LLC (Charlottesville, VA). Ketamine and
xylazine were purchased from Vedco, Inc., (St. Joseph,
MO). In all cases vehicle used was phosphate buffered
saline (PBS).
Dose effect
The appropriate dose of ATL313 for survival studies was
determined by a dose response curve where increasing
doses of ATL313 (5–200 μg/kg) were administered every
6 hours to female BALB/c and C57BL/6 mice after the
intraperitoneal (IP) injection of a lethal dose of O111:B4
LPS (20 mg/kg). A similar dose response curve was used
to determine the optimal dose of LPS for BALB/c and
C57BL/6 mice.
Survival studies
Female C57BL/6 mice were inoculated with 1 × 108 col-
ony forming units (CFU) live K12, O26:B6 E. coli or 8 ×
108 CFU S. aureus at t = 0 and inoculated with the A2A AR
agonist, ATL313 (5 μg/kg), or PBS, at t = 8, and then every
6 hours spanning 48 hours. To determine an optimal dos-
ing interval, ATL313 was administered every 12 hours
spanning 48 hours for S. aureus inoculated mice. A dose of
ceftriaxone (25 mg/kg; t = 8) was given to a subset of
treated and control mice to create a total of four experi-
mental groups (bacterial infection + PBS; bacterial infec-
tion + ATL313; bacterial infection + Ceftriaxone; bacterial
infection + ATL313 + Ceftriaxone). Female BALB/c mice
were also tested in the E. coli model (data not shown).
Female BALB/c mice undergoing endotoxemia were
injected IP with LPS one half hour prior to injection with
ATL313 (5 μg/kg) or PBS which occurred at t = 0 and every
6 hrs thereafter, for a total of eight doses spanning 48
hours (N = 20–29 per group). To provide equal fluid
resuscitation in the setting of sepsis, all injections were IBMC Infectious Diseases 2008, 8:141 http://www.biomedcentral.com/1471-2334/8/141
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mL in volume. Moribund mice were anesthetized using
ketamine and xylazine and euthanized via cervical dislo-
cation.
Time course studies
Female C57BL/6 and BALB/c mice were injected intraperi-
toneally (IP) with O111:B4 LPS and ATL313 or PBS as
described above. Experimental and control animals were
sequentially sacrificed at times 1, 2, 4, 8, and 24 hours
after LPS injection. The mice were anesthetized with keta-
mine and xylazine and killed by cervical dislocation.
Immediately prior to sacrifice the animal underwent car-
diac puncture and ventricular blood was aspirated for
white blood cell analysis via the Hemavet 850 veterinary
multi-species hematology system (Drew Scientific, Inc.,
Oxford, CT) and future cytokine analysis.
Cytokine quantification
Cytokine investigations were carried out using a protein
bead-based multiplex immunoassay system (Bio-Rad Lab-
oratories, Hercules, CA). With this system we are able to
measure IL-1α and β, TNF-α, IFN-γ, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-10, IL-12 p40 and p70, IL-17, KC, MIP-1α, and
RANTES through use of pre-packaged bead arrays. This
panel allows for evaluation of early and late appearing as
well as pro- and anti-inflammatory cytokines.
Statistical analysis
Statistical comparisons of cytokine values were done by a
2 tailed Student's t-Test (Microsoft Excel software, Micro-
soft Corporation, Redmond, WA). Survival data were plot-
ted and the survival curves compared with a log-rank test
(GraphPad PRISM software, San Diego, CA). Data are dis-
played as means ± SEM unless otherwise stated. Differ-
ences were considered significant at p < 0.05.
Results
ATL313 improves survival in three sepsis models
The optimal dose of ATL313 for survival studies was 5 μg/
kg in BALB/c (Figure 1) and C57BL/6 (data not shown)
mice. The survival rate for the four groups inoculated with
live E. coli were: PBS alone, 0%; ATL313 alone, 0% (p =
Dose effect Figure 1
Dose effect. The optimal dose of ATL313 was determined through a dose response curve where PBS vehicle (white dia-
mond), 5 μg/kg ATL313 (black circle), 50 μg/kg ATL313 (black triangle), 100 μg/kg ATL313 (white square), or 200 μg/kg 
ATL313 (asterix) was injected IP every 6 hours into BALB/c mice (N = 4 per group) after a lethal IP dose of LPS O111:B4 (20 
mg/kg).
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0.031 when compared to E. coli alone as time to death was
prolonged); Ceftriaxone alone, 20%; Ceftriaxone plus
ATL313, 100% (p = 0.013 when compared to ceftriaxone
treatment alone) (Figure 2A). A second group of mice
were injected IP with live S. aureus. The survival of mice
treated with the combination of ceftriaxone and ATL313
was 60%, compared to 20% of mice receiving ceftriaxone
alone (p = 0.02) and 13% of vehicle controls (S. aureus vs.
S. aureus + ATL313, p = 0.036) (Figure 2B). Finally, the
survival rate over 7 days of mice injected IP with LPS was
approximately 40%. ATL313 dosed at six hour intervals
beginning one half-hour before LPS increased LPS chal-
lenged mouse survival to approximately 90% (p = 0.005)
(Figure 2C).
ATL313 influences circulating cytokine concentrations 
after LPS challenge
Individual cytokine concentrations displayed statistically
significant differences at different intervals after treatment
with ATL313 when compared to controls. In plasma, at
time (t) = 1 hour, TNF-α concentrations were significantly
higher in untreated animals (N = 7) than treated animals
(p = 0.041) (Figure 3A). Conversely, IL-10 in plasma was
significantly lower at 1 and 2 hours after LPS inoculation
in untreated animals vs. treated animals (p = 0.036 and
0.042 respectively) (Figure 3B). MIP-1α is also attenuated
early on by ATL313. At t = 2 hours, the untreated animals
had a higher concentration of MIP-1α in plasma than
those treated with ATL313 (p = 0.004) (Figure 3C). MCP-
1 values were significantly lower for ATL313 treated ani-
mals at t = 4 hours (p = 0.05) (Figure 3D). IFN-γ appeared
later and was significantly higher at t = 8 hours in animals
exposed only to LPS than in treated animals (p = 0.001)
(Figure 3E). IL-17 was also decreased by ATL313. The dif-
ference was statistically significant at t = 8 (p = 0.043) (Fig-
ure 3F). Although differences between untreated and
treated mice were observed, these did not reach statistical
significance for the following cytokines/chemokines: IL-
1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-12 p40, IL-12 p70,
KC, and RANTES (data not shown). These analytes were
chosen to allow assessment of early and late, and pro- and
anti-inflammatory cytokines.
ATL313 increases peripheral white blood cell 
concentrations in endotoxemic mice
During experimental endotoxemia in BALB/c mice we
found that the concentration of circulating white blood
cells (WBCs) was higher in ATL313 treated animals when
compared to untreated animals. This difference was con-
sistent at all time points and statistically significant at t =
2 hours after LPS injection (p = 0.003) (Figure 4A). This
finding was mirrored by the population of neutrophils
(PMNs) in the blood. The concentration of PMNs in the
blood was also consistently higher at all time points and
statistically significantly higher after 2 hours in animals
treated with ATL313 (p = 0.007) (Figure 4B). As in the
case of total WBCs and PMNs, the trend towards higher
concentration of peripheral blood cells across all time
periods in treated animals was true for lymphocytes as
well. At t = 8, the concentration difference between
untreated and treated (N = 6) resulted in a p value = 0.05
(data not shown).
Discussion
This study documents: 1) a survival benefit with adminis-
tration of ATL313 during live E. coli and S. aureus sepsis
(in conjunction with an antibiotic) and in LPS-induced
sepsis; 2) a decrease of TNF-α, MIP-1α, MCP-1, IFN-γ, and
IL-17 blood concentrations in animals receiving A2A AR
agonists with a concordant increase in IL-10 concentra-
tions; and 3) a relative increase in circulating peripheral
blood leukocyte concentrations in mice receiving ATL313
when compared to controls. The first observation bears on
the generalizability of our observations to different etiol-
ogies of sepsis, including both gram positive and gram
negative infections, while the latter two emphasize the
mechanism(s) of protection. While these results are
encouraging, further work is needed to prove the efficacy
of these compounds in clinical sepsis and other models of
sepsis including cecal ligation and puncture.
In our murine model of LPS-induced sepsis, TNF-α blood
concentrations rise rapidly and are profoundly decreased
by the co-administration of an A2A AR agonist, ATL313.
We have previously shown that the administration of an
A2A AR agonist up to 24 hours after LPS challenge is still
protective (i.e. improved survival) when TNF-α concen-
trations in blood have returned to baseline; therefore the
benefit cannot be attributed to effects on TNF-α alone
[12]. Given the same argument, it is unlikely that the
decrease in MIP-1α, MCP-1, IFN-γ or IL-17 completely
explains the protective efficacy of A2A AR agonists in exper-
imental murine sepsis. However, the effect of A2A AR ago-
nists on multiple cytokines is encouraging, since the
clinical presentation of sepsis in humans is highly variable
with regard to the cytokine cascade, but other as yet unde-
termined targets may play a role as well.
Inoculation of experimental animals with TNF-α alone
reproduces many of the fundamental pathophysiologic
alterations typical of sepsis [13]. In vivo, TNF-α alters
endothelium and is a potent chemoattractant for neu-
trophils which contributes to the pathology of venous
thromboses, arteriosclerosis, vasculitis, and disseminated
intravascular coagulation [14,15]. By decreasing TNF-α
expression, A2A  AR agonists may decrease neutrophil
recruitment and therefore inflammatory damage to the
endothelium. This conjecture is bolstered by the increased
number of neutrophils in the circulation of mice treated
with ATL313 after LPS challenge. Our findings are mir-BMC Infectious Diseases 2008, 8:141 http://www.biomedcentral.com/1471-2334/8/141
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Figure 2 (see legend on next page)
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rored by in vitro and in vivo work which revealed that A2A
AR agonists decreased neutrophil extravasation and their
release of oxidative and non-oxidative products in experi-
mental gram negative bacterial meningitis and S. aureus
septic arthritis [16,17].
Cytokines can cause inflammation via upregulation of
other pro-inflammatory cytokines in the case of TNF-α,
MIP-1α and IL-17, modulation of T-cells by IFN-γ, and
activation of monocytes by MCP-1 [18-21]. These pro-
inflammatory mechanisms result in recruitment and acti-
vation of neutrophils, NK cells, and macrophages which
produce deleterious reactive oxygen species and lyso-
somal enzymes [22-25]. TNF-α, MIP-1α, MCP-1, and IFN-
γ have been measured in patients with sepsis and acute
respiratory distress syndrome and are correlated with poor
outcomes [14,26,27]. Antibodies to MIP-1α, IL-17, and
IFN-γ have ameliorative in vivo effects in animal sepsis
studies [28-32]. As in the case of TNF-α, A2A AR agonists
down-regulate the expression of MIP-1α, MCP-1, IFN-γ,
and IL-17 with a concurrent survival benefit.
While pro-inflammatory cytokines such as TNF-α, MIP-
1α, MCP-1, IFN-γ, and IL-17 increase the inflammatory
response, anti-inflammatory cytokines such as IL-10 tem-
per this response. IL-10 is produced primarily by Th-2
cells and decreases concentrations of TNF-α by degrading
cytokine mRNA [33]. IFN-γ production is thought to be
inhibited by IL-10 in a more indirect manner through the
suppression of IL-12 production [34].
IL-10 reduces the release of TNF-α into the circulation
which hinders the development of a systemic inflamma-
tory response syndrome, and this correlates with an
increase in survival [35-38]. We have found that elevated
IL-10 and decreased TNF in the first few hours of experi-
mental sepsis is correlated with increased survival. It is
possible that the decrease in pro-inflammatory cytokines
occurs as a direct result of the increase in IL-10 when an
animal is treated with ATL313. Given the changes in IL-10
expression in endotoxemic mice after treatment with an
A2A AR agonist in C57BL/6 mice, we studied survival in a
predominantly Th2 T-lymphocyte populated mouse, e.g.
BALB/c. Again, we showed a significant survival benefit in
these animals treated with an A2A AR agonist after live E.
coli or LPS O111:B4 injection.
Therefore, the benefit of ATL313 in these sepsis models is
equally beneficial in mice with a Th1 or Th2 phenotype,
perhaps implying that ATL313 and similar compounds
exert their anti-inflammatory effect through modification
of the innate immune system. We are actively pursuing
this line of investigation. Additionally, targeting individ-
ual cytokines alone has not been clinically successful, but
a more pluripotent approach such as is offered by A2A AR
agonists may be more successful. The influence of A2A AR
agonists on late mediators including triggering receptor
expressed on myeloid cells (TREM-1) and High mobility
group box 1 (HMGB1) should be investigated and is the
subject of our ongoing research efforts.
Conclusion
Collectively, we have shown that the effect of A2A AR ago-
nists spans different mouse strains, different LPS prepara-
tions, as well as different formulations of A2A AR agonists.
We also investigated a model of S. aureus sepsis and saw a
survival benefit after treatment with ATL313 and ceftriax-
one when compared to ceftriaxone alone. A2A AR agonists
provide an avenue to study the inflammation due to sep-
sis and should be considered for clinical interventions in
septic patients. Ultimately, it will be important to deline-
ATL313 protects mice in three different sepsis models Figure 2 (see previous page)
ATL313 protects mice in three different sepsis models. ATL313 protects mice from live E. coli challenge. Mice were 
injected with 1 × 108 CFU of live E. coli. Mice (N = 5 per group) were treated with PBS vehicle (white diamond), ATL313 (black 
circle), the antibiotic ceftriaxone (white triangle), or a combination of ceftriaxone and ATL313 (black square). Ceftriaxone was 
administered at a single dose of 25 mg/kg eight hours following inoculation. ATL313 (5 μg/kg) or PBS was dosed IP starting 8 
hours after E. coli injection then every 6 hours spanning 48 hours. ATL313 + ceftriaxone treatment protects mice better than 
ceftriaxone treatment alone (* p = 0.013) and treatment with ATL313 alone prolongs life compared to E. coli untreated con-
trols (#p = 0.031) (A). ATL313 protects mice from live S. aureus challenge. Mice were injected IP with 8 × 108 cfu of live S. 
aureus. Mice (N = 10–24 per group) were treated with PBS vehicle (white diamond), ATL313 (black circle), the antibiotic ceftri-
axone (white triangle), or a combination of ceftriaxone and ATL313 (black square). Ceftriaxone was administered at a single 
dose of 25 mg/kg eight hours following inoculation. ATL313 (5 μg/kg) or vehicle was dosed IP starting at eight hours after S. 
aureus injection 4 times at 12 hour intervals. ATL313 + ceftriaxone treatment protects mice better than ceftriaxone treatment 
alone (* p = 0.02) and ATL313 treatment alone increases survival in S. aureus untreated controls (#p = 0.036) (B). ATL313 
decreases LPS-induced mouse mortality via A2A AR-mediated mechanisms. Mice (N = 20–29 per group) were injected IP with 
LPS from E. coli (O111:B4, 5 mg/kg). One half hour prior to LPS challenge and at 6 hr intervals, PBS vehicle (white triangle) or 
ATL313 (black circle) was injected (5 μg/kg) IP for a total of 8 doses/48 hr. ATL313 protects the mice compared to LPS-chal-
lenged mice in the absence of ATL313 (* p = 0.005) (C).BMC Infectious Diseases 2008, 8:141 http://www.biomedcentral.com/1471-2334/8/141
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ATL313 affects circulating cytokines and chemokines Figure 3
ATL313 affects circulating cytokines and chemokines. The A2A AR agonist, ATL313 significantly decreases the concen-
trations of pro-inflammatory cytokines and chemokines in mice (N = 5–9 per group) after inoculation with E. coli O111:B4 LPS 
(25 mg/kg). Mean ± standard error of the mean concentrations are shown in pg/mL. In ATL313 treated animals, TNF-α, at t = 
1 hour, was significantly lower than in untreated animals (* p = 0.041) (A). Conversely, the anti-inflammatory cytokine, IL-10, 
had an increase in concentration in ATL 313 treated animals at t = 1 and 2 hours (* p = 0.036; # p = 0.042) (B). Like TNF-α, 
MIP-1α concentrations are increased early on after LPS exposure and significantly decreased by ATL313 at t = 2 hours (* p = 
0.004) (C). Increases in MCP-1 concentrations occur later after exposure to LPS and are significantly decreased by ATL313 at 
t = 4 hours (* p = 0.05) (D). Both IFN-γ and IL-17 concentrations are maximal at t = 8 hours and are significantly attenuated by 
ATL313 at that time (* p = 0.001 and 0.043 respectively) (E and F).
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ATL313 affects circulating white blood cells Figure 4
ATL313 affects circulating white blood cells. ATL313 (black circle) increases concentrations of circulating white blood 
cells in mice (N = 6 per group) after inoculation with LPS from E. coli (O111:B4, 5 mg/kg) (A). Additionally, circulating neu-
trophil (PMN) concentrations are also increased in mice treated with ATL313 (black circle) after LPS inoculation (B). Mean ± 
standard error of the mean concentrations are shown in K/μL. The difference in concentrations is significantly different at t = 2 
hours for both total WBC and PMN concentrations (* WBC p = 0.003; PMN p = 0.007).
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ate which cytokines and cells are the effectors of this anti-
inflammatory effect.
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